Lionco Pharmaceutical Group Co., Ltd. (603669.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 5.81

From 52W high−33.54%

Volume63.79M

Market capCNY 3.84B

P/E (TTM)−19.9x

P/S (TTM)11.1x

Div yield—

Key dataSep 18, 2026

Open

CNY 5.81

From 52W high

−33.54%

Volume

63.79M

Market cap

CNY 3.84B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−24.0x

P/E (TTM)

−19.9x

RSI (14)

51.9

MomentumView details →

1D Return

−1.64%

YTD Return

+22.37%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−19.9x

EV/EBITDA

−24.0x

EV/Sales

10.8x

P/S (TTM)

11.1x

P/B (TTM)

6.6x

ProfitabilityView details →

Gross Margin

42.32%

Net Margin

−47.83%

EBITDA Margin

−44.97%

ROE (TTM)

−27.54%

ROA (TTM)

−15.30%

Asset Turnover

0.32x

GrowthView details →

Revenue YoY

+1.66%

EPS YoY

−28.70%

FCF YoY

−39.91%

Revenue CAGR 3Y

+3.69%

EPS CAGR 3Y

−50.00%

EBITDA YoY

—

MomentumView details →

1D Return

−1.64%

YTD Return

+22.37%

1Y Return

−3.79%

RSI (14)

51.9

vs 50D SMA

−2.86%

vs 200D SMA

+12.00%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

1.15x

Quick Ratio

0.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

−50.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

358.90M

Net Income (TTM)

−171.66M

Op. CF (TTM)

−148.53M

Latest newsMore news →

Lingkang Pharmaceutical reported its 2026 half-year results, with revenue of 257 million yuan, up 50.03% year-on-year, and net profit attributable to shareholders of 21.11 million yuan, turning from a loss to a profit.37d ago

Lingang Pharmaceutical announced its 2026 first-half results, reporting a net profit of 21.1127 million yuan, turning around from a loss in the prior year.37d ago

Similar companies

Shandong Xinhua Pharmaceutical Company Limited00719.HK 司太立603520.SH 卫信康603676.SH 康惠股份603139.SH Indivior Pharmaceuticals IncINDV 威尔药业603351.SH Find similar companies →

Latest newsMore news →

Lingkang Pharmaceutical reported its 2026 half-year results, with revenue of 257 million yuan, up 50.03% year-on-year, and net profit attributable to shareholders of 21.11 million yuan, turning from a loss to a profit.37d ago Lingang Pharmaceutical announced its 2026 first-half results, reporting a net profit of 21.1127 million yuan, turning around from a loss in the prior year.37d ago Lingang Pharmaceutical's subsidiary Lingang Pharma's product Huperzine A for injection (brand Ruilisu) was selected in a provincial alliance centralized procurement led by Henan Province, with a 2-year procurement cycle.39d ago